Patent Granted for EKF Diagnostics HemoPoint H2 Cuvettes

EKF Diagnostics Holdings plc announced yesterday that it has been granted a patent in the US for its HemoPoint H2 cuvettes. The cuvettes are intended for use with the HemoPoint H2, point-of-care hemoglobin measurement system (known as Hemo Control outside of the US).

EKF announced in November 2011 that it had received CLIA waived status from the US Food and Drug Administration (FDA) for the HemoPoint H2 analyzer. This allowed Alere Inc., the exclusive distributor of the product, to begin marketing the analyzer in the US.

Commenting, Julian Baines, CEO of EKF Diagnostics Holdings plc, said: “The granting of the Patent in the US for our cuvettes provides important protection for our unique product as it is sold into the US haemoglobin testing market by our US partner Alere.”